Search
Elicio Therapeutics Inc
ELTXAdd to Watchlist
5.140USD
+1.230+31.46%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
98.10MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Elicio Therapeutics Inc is 8.00, ranking 166 out of 387 in the Biotechnology & Medical Research industry. The average price target is 15.50, with a high of 18.00 and a low of 13.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
20.667
Target Price
+428.56%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Elicio Therapeutics Inc
ELTX
4
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Elicio Therapeutics Inc's price target?
Analysts forecast that Elicio Therapeutics Inc's price target is USD 15.50, with the highest forecast at USD 18.00 and the lowest forecast at USD 13.00.
How have Elicio Therapeutics IncELTX's recent earnings per share performed?
The market expectation was USD -0.65, while Elicio Therapeutics IncELTX's earnings per share (EPS) for the previous quarter was USD -0.50. EPS for the next quarter is expected at USD -0.54.
What is the analyst rating for Elicio Therapeutics Inc?
Based on the ratings of Elicio Therapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.